| 1 Pain (0‐30) change |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 1.1 End of treatment at week 6 |
1 |
59 |
Mean Difference (IV, Fixed, 95% CI) |
4.0 [0.98, 7.02] |
| 2 Function (0‐30) change |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 2.1 End of treatment at week 6 |
1 |
59 |
Mean Difference (IV, Fixed, 95% CI) |
0.60 [‐1.95, 3.15] |
| 3 Range of motion (0‐10) change |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 3.1 End of treatment at week 6 |
1 |
59 |
Mean Difference (IV, Fixed, 95% CI) |
0.3 [‐0.06, 0.66] |
| 4 Total Larson rating score (0‐77) change |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 4.1 End of treatment at week 6 |
1 |
59 |
Mean Difference (IV, Fixed, 95% CI) |
5.9 [1.31, 10.49] |
| 5 Patient global (number of patients symptom free or markedly improved) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 5.1 14 to 26 weeks post‐injection |
1 |
57 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.65 [1.03, 2.66] |
| 6 Safety: total withdrawals overall |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 6.1 14 to 26 weeks post‐injection |
1 |
60 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.41 [0.04, 4.27] |
| 7 Safety: adverse events due to study medication |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 7.1 14 to 26 weeks post‐injection |
1 |
60 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.45 [0.54, 11.19] |
